Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Estramustine · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Paclitaxel | DRUG | - |
| Estramustine | DRUG | - |
| Carboplatin | DRUG | - |
Inclusion Criteria: * Adenocarcinoma of the prostate not curable with local treatment * Disease progression while receiving hormonal therapy * Measurable or evaluable disease * Previous treatment with a maximum of one prior chemotherapy regimen * ECOG performance status 0, 1, or 2. * Adequate bone ...
Top 20 of 53 competitors
Estramustine is a small molecule being studied for the treatment of prostate cancer. It is currently in Phase 2 clinical development as an investigational therapy. The drug is being evaluated in combination with other agents for hormone refractory prostate carcinoma, a form of prostate cancer that no longer responds to hormone therapy.
Estramustine is being developed by Bristol-Myers Squibb Company, which trades under the ticker symbol BMY. The company is conducting clinical research to evaluate the drug's safety and efficacy in patients with prostate cancer.
Estramustine is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 2 clinical trial has been completed to assess its use in prostate cancer.
Estramustine has been studied in one completed Phase 2 clinical trial registered as NCT00193193. The trial, titled 'Weekly Paclitaxel, Low-Dose Estramustine, and Carboplatin in the Treatment of Hormone Refractory Prostate Carcinoma,' enrolled 100 participants with prostate cancer.
Estramustine is the active drug entity. It is often administered as estramustine phosphate, a prodrug form that is converted to estramustine in the body. In clinical research, the drug may be referred to by either name, but they represent the same therapeutic agent.